Trial Profile
Immunological Targeting of CD-133 in Recurrent Glioblastoma: A Multi-center Phase I Translational and Clinical Study of an Autologous CD-133 DC Vaccine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs ICT 121 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors ImmunoCellular Therapeutics
- 09 Aug 2018 Status changed from active, no longer recruiting to completed.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2017 Results (n=20) from this trial published in an ImmunoCellular Therapeutics Media Release.